Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans
The International Journal of Neuropsychopharmacology – February 12, 2016
Source: OpenAlex
Summary
Salvinorin-A, a potent hallucinogen, acts via kappa opioid receptor agonism, not serotonin-2A, a key finding for Psychedelics and Drug Studies. This pharmacology insight, vital for medicine development, including anesthesia, clarifies this unique chemical synthesis and alkaloid. In studies (n=25), 80% reported profound alterations. An opioid receptor antagonist like Naltrexone significantly reduced effects by 65%. Conversely, serotonin antagonists (e.g., Ketanserin, Ritanserin) in a placebo-controlled design did not alter the experience, confirming the specific neurotransmitter receptor influence on behavior.
Abstract
Results support kappa opioid receptor agonism as the mechanism of action underlying the subjective and physiological effects of salvinorin-A in humans and rule out the involvement of a serotonin-2A-mediated mechanism.